Key Market Insights

• Presently, nearly 570 companies, across the globe, offer services for the manufacturing of different types of oral solids.
• Nearly 50% of the aforementioned service providers are based in the Asia-Pacific region, followed by the players located in Europe (29%).
• The oral solid dosage contract manufacturing industry is dominated by the presence of mid-sized players (51-200 employees), which represent around 40% of the total contract manufacturers.
• Nearly 15% players claim to act as one-stop shops, offering services, ranging from formulation and process development to the analytical testing, scale-up, and packaging of oral solids.
• Over 85 expansion initiatives were undertaken in the period 2018-2022; close to 50% of the total number of expansions were undertaken in North America.
• More than 50% of the annual, global oral solid dosage contract manufacturing capacity (in terms of number of finished dosages) belongs to very large players with over 10,000 employees.
• Nearly 45% of the global outsourced commercial demand is anticipated to be driven by oral solids intended to target oncological indications.
• The oral solid dosage contract manufacturing market is likely to grow at a CAGR of ~5%, till 2035; the projected opportunity is likely to distributed across various dosage types, primary packaging, company sizes, scales of operation, therapeutic areas and geographical areas.
• North America and Europe are anticipated to capture around 85% of the market share, till 2035.
• In terms of type of finished dosage form, the current market is driven by tablet manufacturing (close to 60%); this trend is unlikely to change in the foreseen future.

Table of Contents

1. PREFACE

1.1.           Introduction

1.2.           Key Market Insights

1.3.           Scope of the Report

1.4.           Research Methodology

1.5.           Frequently Asked Questions

1.6.           Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1.           Chapter Overview

3.2.           Type of Dosage Forms

3.3.           Overview of Oral Solid Dosage Forms

3.4.           Overview of Oral Solid Contract Manufacturing

3.5.           Future Perspectives

4. ORAL SOLID DOSAGE MANUFACTURING ORGANIZATIONS (CMOs):

           MARKET LANDSCAPE

4.1.           Chapter Overview

4.2.           Oral Solid Dosage CMOs: List of Companies

5. COMPANY COMPETITIVENESS ANALYSIS

5.1.           Chapter Overview

5.2.           Assumptions and Key Parameters

5.3.           Methodology

        5.4.           Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers in North America

5.5.           Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Europe

5.6.           Company Competitiveness Analysis: Oral Solid Contract Manufacturers based in Asia-Pacific and Rest of the World

5.7.           Company Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers

6. REGIONAL CAPABILITY ANALYSIS

6.1.           Chapter Overview

6.2.           Key Assumptions and Methodology

6.3.           Overall Landscape of Oral Solid Dosage Contract Manufacturing Facilities

6.4.           Oral Solid Dosage Contract Manufacturers in North America

6.5.           Oral Solid Dosage Contract Manufacturers in Europe

6.6.           Oral Solid Dosage Contract Manufacturers in Asia-Pacific and Rest of the World

7. COMPANY PROFILES

7.1.           Chapter Overview

7.2.           Oral Solid Dosage Contract Manufacturing Service Providers: North America

7.2.1.        Alcami

7.2.1.1.     Company Overview

7.2.1.2.     Service Portfolio

7.2.1.2.1.  Manufacturing Capabilities and Facilities

7.2.1.3.     Recent Developments and Future Outlook

7.2.2.        Cambrex

7.2.3.        Catalent

7.3.           Oral Solid Dosage Contract Manufacturing Service Providers: Europe

7.3.1.        Aenova

7.3.2.        Almac

7.3.3.        Lonza

7.4.           Oral Solid Dosage Contract Manufacturing Service Providers: Asia-Pacific and Rest of the World

7.4.1.        Hetero Drugs

7.4.2.        Ind-Swift Laboratories

7.4.3.        Rubicon Research

8. MAKE VERSUS BUY DECISION FRAMEWORK

8.1.           Chapter Overview

8.2.           Assumptions and Key Parameters

8.3.           Oral Solid Dosage Manufacturers: Make versus Buy Decision Making

8.4.           Concluding Remarks

9. RECENT EXPANSIONS

9.1.           Chapter Overview

9.2.           Oral Solid Dosage Contract Manufacturers: Recent Expansions

10. CAPACITY ANALYSIS

10.1.         Chapter Overview

10.2.         Key Assumptions and Methodology

11. DEMAND ANALYSIS

11.1.         Chapter Overview

11.2.         Key Assumptions and Methodology

11.3.         Overall Annual Demand for Oral Solids, 2023-2035

11.4.         Annual Outsourced Commercial Demand for Oral Solids, 2023-2035

11.5.         Annual Outsourced Clinical Demand for Oral Solids, 2023-2035

11.6.         Correlation between Annual Demand and Capacity

12. TOTAL COST OF OWNERSHIP FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS

12.1.         Chapter Overview

12.2.         Key Parameters

12.3.         Assumptions and Methodology

12.4.         Sample Dataset for the Estimation of Total Cost of Ownership

12.5.         Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20

12.6.         Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by CapEx and OpEx, Y0 and Y20

12.7.         Concluding Remarks

13. REGULATORY LANDSCAPE FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURERS

13.1.         Chapter Overview

13.2.         Regulatory Guidelines in North America

13.3.         Regulatory Guidelines in Europe

13.4.         Regulatory Guidelines in Asia-Pacific and Rest of the World

13.5.         Oral Solid Dosage CMOs: Information on Approval from Various Regulatory Authorities

13.6.         Bubble Analysis: Regional Regulatory Summary

14. CASE STUDY ON TASTE MASKING SERVICES AND TECHNOLOGIES: MARKET LANDSCAPE

14.1.         Chapter Overview

14.2.         Taste Masking and Taste Assessment Service Providers

14.3.         Taste Masking and Taste Assessment Services: Overall Market Landscape

15. CASE STUDY ON BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES: MARKET LANDSCAPE

15.1.         Chapter Overview

15.2.         Bioavailability Enhancement Service Providers: Overall Market Landscape

16. MARKET FORECAST

16.1.         Chapter Overview

16.2.         Forecast Methodology and Key Assumptions

17. EXECUTIVE INSIGHTS

18. CONCLUDING REMARKS

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/oral-solid-dosage-manufacturing-market.html

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

[email protected]